Jazz Pharmaceuticals JAZZ along with partner Zymeworks ZYME announced positive tolerability and efficacy results from an ongoing phase II study on zanidatamab, an investigational HER2-targeted ...
June 20 (Reuters) - Jazz Pharmaceuticals (JAZZ.O), opens new tab said on Thursday its experimental drug to treat a common movement disorder failed to reduce tremor severity in a mid-stage study, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback